文献速递肝病

肝硬化中的微生物群及其在肝功能失代偿中的作用

The microbiota in cirrhosis and its role in hepatic decompensation.
PubMed 文献 · J Hepatol · 2021-01-01

本综述聚焦肠道细菌过度生长与菌群失调在肝硬化失代偿中的核心作用,阐述细菌毒素直接致肝细胞死亡、菌群失调损害肠屏障并增加细菌易位,进而引发感染、全身炎症和血管扩张,促成急性失代偿、pre-ACLF和ACLF。30%患者无可识别诱因,推测肠道菌群易位是全身炎症和失代偿的原因。靶向微生物群的策略包括利福昔明、粪菌移植和肠道吸附剂(如Yaq-001),有望用于预防和治疗急性失代偿。

要点

  • 肠道菌群失调和细菌易位是肝硬化失代偿的关键驱动因素
  • 30%的pre-ACLF和ACLF患者无可识别诱因,推测菌群易位参与
  • 靶向微生物群策略包括利福昔明、粪菌移植和肠道吸附剂Yaq-001

核心结论

  • 靶向微生物群是预防和治疗肝硬化急性失代偿、pre-ACLF和ACLF的有前景策略。

研究设计与样本

  • 本文为综述,聚焦微生物群在肝硬化失代偿中的作用及靶向微生物群的策略。

主要发现

  • 肠道细菌过度生长和菌群失调是肝硬化相关事件 cascade 的核心环节。
  • 细菌毒素进入门脉或体循环可直接导致肝细胞死亡。
  • 菌群失调影响肠屏障功能并增加细菌易位,导致感染、全身炎症和血管扩张,促成急性失代偿和器官衰竭。
  • pre-ACLF和ACLF以突发器官功能障碍(和衰竭)及高短期死亡率为特征,常由确诊细菌感染和/或严重酒精性肝炎诱发。
  • 30%的pre-ACLF和ACLF患者无可识别诱因,推测肠道菌群易位导致全身炎症和失代偿。

关键数值与推荐

  • 不同微生物群谱可能影响失代偿速率及患者结局。
  • 靶向微生物群的方法包括抗生素(如利福昔明)、粪菌移植和肠道吸附剂(如Yaq-001),后者结合微生物因子而不直接影响细菌生长动力学。

临床怎么用

  • 临床可关注微生物群靶向策略用于预防和治疗肝硬化急性失代偿、pre-ACLF和ACLF。
  • 对无可识别诱因的pre-ACLF和ACLF患者,应考虑肠道菌群易位的可能作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cirrhosis - the common end-stage of chronic liver disease - is associated with a cascade of events, of which intestinal bacterial overgrowth and dysbiosis are central. Bacterial toxins entering the portal or systemic circulation can directly cause hepatocyte death, while dysbiosis also affects gut barrier function and increases bacterial translocation, leading to infections, systemic inflammation and vasodilation, which contribute to acute decompensation and organ failure. Acute decompensation and its severe forms, pre-acute-on-chronic liver failure (ACLF) and ACLF, are characterised by sudden organ dysfunction (and failure) and high short-term mortality. Patients with pre-ACLF and ACLF present with high-grade systemic inflammation, usually precipitated by proven bacterial infection and/or severe alcoholic hepatitis. However, no precipitant is identified in 30% of these patients, in whom bacterial translocation from the gut microbiota is assumed to be responsible for systemic inflammation and decompensation. Different microbiota profiles may influence the rate of decompensation and thereby outcome in these patients. Thus, targeting the microbiota is a promising strategy for the prevention and treatment of acute decompensation, pre-ACLF and ACLF. Approaches include the use of antibiotics such as rifaximin, faecal microbial transplantation and enterosorbents (e.g. Yaq-001), which bind microbial factors without exerting a direct effect on bacterial growth kinetics. This review focuses on the role of microbiota in decompensation and strategies targeting microbiota to prevent acute decompensation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021. PMID: 34039493. doi:10.1016/j.jhep.2020.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。